Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398515 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00398515: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00398515 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00398515, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of temsirolimus when given together with lenalidomide in treating patients with previously treated multiple myeloma. Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Temsirolimus may also stop the growth of cancer cells by blocking some of the enzymes needed for their growth. Giving lenalidomide together with temsirolimus may kill more cancer cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG lenalidomide
- OTHER pharmacological study
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00398515
The ClinicalTrials.gov registry entry for NCT00398515 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00398515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00398515 about?
NCT00398515 is a clinical study titled "Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma". This phase I trial is studying the side effects and best dose of temsirolimus when given together with lenalidomide in treating patients with previously treated multiple myeloma. Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, su...
What is the current status of trial NCT00398515?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-03.
What interventions are being tested in trial NCT00398515?
The interventions under investigation include: laboratory biomarker analysis (OTHER), lenalidomide (DRUG), pharmacological study (OTHER), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00398515?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.